CMAB Biopharma Secures $34 Million Series B Financing

Apr  2018

CMAB Biopharma Inc. (CMAB), a full-service contract development and manufacturing organization (CDMO) providing process development and manufacturing services for biologic products

SUZHOU, China, April 02, 2018  (GLOBE NEWSWIRE)  -- CMAB Biopharma Inc. (CMAB), a full-service  contract development and  manufacturing organization (CDMO) providing process development  and manufacturing  services for biologic products,  today announced that the company has  raised $34 million in Series B nancing.

The round is being led by CD Capital, and jointly participated by C-Bridge Capital, Cormorant, Qianhai  FoF  Fund  and  Tigermed. The  funding  proceeds will be  used to upgrade CMAB’s 2,000L Good Manufacturing Practices  (GMP) facilities,  expand manufacturing capacity and will also enable the company to provide 50L/200L/500L/1,000L/2,000L bioreactor scale GMP manufacturing services.

Located in  Suzhou’s  BioBAY  Park,  CMAB’s  new  manufacturing facility  will provide services for the development of manufacturing process, analytical method, formulation, and the manufacture of biologic  drug substances and drug products. The initial facility will be able  to generate pre-clinical  and  early-stage clinical (Phase I/II) products, using manufacturing that  follows  global GMP standards, including  those of the China Food & Drug Administration, US Food  &  Drug  Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards.

In the  company’s  recent grand  opening,   CMAB also  announced it has  entered into collaboration agreements with several leading  biopharma companies, which speaks to the quality of CMAB’s services and to the expertise of its management team.

“The  closing  of  this   round   is  an  important  milestone  for  CMAB and   reects  the signicant achievements we  have  made in developing the  company into  a  preferred CDMO partner,”  said  Mr. Qibin Liang, President of CMAB. “We aim  to  bring  our  client expertise and  knowledge to eciently  advance products from  concept into the  clinic. This nancing furthers our vision to become a fully-integrated CDMO platform providing clinical and  commercial production services to the  Chinese domestic and  the international biologics markets.”

Mr. Qing Tan, founding partner of CD Capital, said, “CMAB has  quickly established itself as a force  in CDMO industry.  We are delighted to lead this nancing and support CMAB in  its  mission  to  enable  clients  to  take   their  innovative   concepts for  tomorrow’s medicines from  DNA to clinical product today, not only in China, but globally. It is well accorded with CD Capital’s investment strategy.”

About CMAB:

CMAB is  a  exible  full-service  CDMO dedicated to  providing  bespoke development manufacturing services of antibodies and  biologics for clients in China and  across the globe.  Our adaptable, service-oriented business enables clients to take  their innovative concepts for  tomorrow’s medicines from  DNA to  clinical  product today.  To nd  out more about our dynamic new CDMO, please go to the website:

About CD Capital:

CD Capital   is  a  venture   capital   founded  in  2013,   specialized  in  the   medical and healthcare investment. It is  currently  managing multiple  USD and  RMB funds,  with asset  under   management  of   over   RMB  4  Billion.  CD  Capital   is   operated  by  a professional team with diversied and  profound industry  background. It has  made investment in more  than  30  high-potential companies  and  realized  multiple  exits.  CD Capital  benets from  China  market by  leveraging  global  technology and  business model.  Learn more at

About C-Bridge:

C-Bridge Capital  is a healthcare dedicated private  equity  rm, focused on growth  and late stage investment opportunities with US$800 million of Assets Under Management. C-Bridge Capital’s current portfolio  includes China’s leading  players in pharmaceuticals, medical devices, diagnostics and healthcare services. C-Bridge Capital is committed to support  commercialization of  cutting   edge   technologies and  companies that   fulll unmet medical needs, thus  continuously improving  the standard and quality of care  for patients. Learn more at



Tel: (86) 0512-69566088

Address: Bld. C37, No. 188 Dong Ping Road, Su Zhou Industry  Campus


CMAB BioPharma (Su Zhou) Inc.


James Cen Bonsor Investor Relations Director C-Bridge Capital

+86 186 1687 3122

In the U.S. James Heins

Senior Vice President

ICR Healthcare (203) 856-2121

In China: Edmond Lococo  Senior Vice President ICR Asia


Phone:  (86) 10 6583 7510
© 2020 CBC Group. All Rights Reserved.